Biblio
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2015:1-5.
BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA. Biol Blood Marrow Transplant. 2019.
Comparison of Two Doses of Antithymocyte Globulin in Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Biol Blood Marrow Transplant. 2019.
Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019.
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629-637.
A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma. Biol Blood Marrow Transplant. 2020.
Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2022.
Secondary impact of the COVID-19 pandemic on patients and the cell therapy healthcare ecosystem. Transplant Cell Ther. 2022.